Iodoquinol | CAS#83-73-8 | Antiseptic | Halogenated 8-Quinolinol

MedKoo Cat#: 531026 | Name: Iodoquinol

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Iodoquinol is one of the halogenated 8-quinolinols that's widely used as an intestinal antiseptic, especially as an antiamebic agent. Iodoquinol is also used topically in other infections and may cause central nervous system and eye damage.

Chemical Structure

Iodoquinol

CAS#83-73-8 (free base)

Theoretical Analysis

MedKoo Cat#: 531026

Name: Iodoquinol

CAS#: 83-73-8 (free base)

Chemical Formula: C9H5I2NO

Exact Mass: 396.8460

Molecular Weight: 396.95

Elemental Analysis: C, 27.23; H, 1.27; I, 63.94; N, 3.53; O, 4.03

Price and Availability

Size	Price	Availability	Quantity
1g	USD 250.00	2 Weeks
5g	USD 450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

53341-25-6 (sodium) 83-73-8 (free base)

Synonym

Iodoquinol, Diiodohydroxyquin, Diiodoquin, Diquinol, Sebaquin

IUPAC/Chemical Name

5,7-diiodoquinolin-8-ol

InChi Key

UXZFQZANDVDGMM-UHFFFAOYSA-N

InChi Code

InChI=1S/C9H5I2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H

SMILES Code

OC1=C2N=CC=CC2=C(I)C=C1I

Appearance

Light yellow to brown crystalline solid.

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Diiodohydroxyquinoline is a topical therapeutic agent, with satisfactory antibacterial properties.

In vitro activity:

The purpose of this study is to assess the activity of FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, remdesivir, and hydroxychloroquine as potential SARS-CoV-2 main protease inhibitors. The calculations revealed that cetilistat, abiraterone, diiodohydroxyquinoline, and bexarotene inhibit main protease and ACE2 receptors more effectively than the well-known drug hydroxychloroquine when used against COVID-19. Reference: Inform Med Unlocked. 2021;26:100745. https://pubmed.ncbi.nlm.nih.gov/34568544/

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMSO	16.9	42.61
	Water	0.7	1.69

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 396.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Shahabadi N, Zendehcheshm S, Mahdavi M, Khademi F. Inhibitory activity of FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, remdesivir, and hydroxychloroquine on COVID-19 main protease and human ACE2 receptor: A comparative in silico approach. Inform Med Unlocked. 2021;26:100745. doi: 10.1016/j.imu.2021.100745. Epub 2021 Sep 22. PMID: 34568544; PMCID: PMC8455240. 2. Borba-Santos LP, Vila T, Rozental S. Identification of two potential inhibitors of Sporothrix brasiliensis and Sporothrix schenckii in the Pathogen Box collection. PLoS One. 2020 Oct 14;15(10):e0240658. doi: 10.1371/journal.pone.0240658. PMID: 33052959; PMCID: PMC7556523.

In vitro protocol:

In vivo protocol:

TBD

1: Fisher AK, Walter FG, Szabo S. Iodoquinol associated seizures and radiopacity. J Toxicol Clin Toxicol. 1993;31(1):113-20. PubMed PMID: 8433407. 2: Yamamoto A, Debrah-Pinamang M, DiModica NJ, Kurogi K, Naqvi AA, Hui Y, Sakakibara Y, Suiko M, Liu MC. Identification and Characterization of the Human Cytosolic Sulfotransferases Mediating the Sulfation of Clioquinol and Iodoquinol. Drug Metab Lett. 2016;10(3):200-205. PubMed PMID: 27449410. 3: Burnett BP, Mitchell CM. Antimicrobial activity of iodoquinol 1%-hydrocortisone acetate 2% gel against ciclopirox and clotrimazole. Cutis. 2008 Oct;82(4):273-80. PubMed PMID: 19055171. 4: Nagata N, Marriott D, Harkness J, Ellis JT, Stark D. In vitro susceptibility testing of Dientamoeba fragilis. Antimicrob Agents Chemother. 2012 Jan;56(1):487-94. doi: 10.1128/AAC.05125-11. Epub 2011 Oct 24. PubMed PMID: 22024820; PubMed Central PMCID: PMC3256011. 5: Chan FT, Guan MX, Mackenzie AM, Diaz-Mitoma F. Susceptibility testing of Dientamoeba fragilis ATCC 30948 with iodoquinol, paromomycin, tetracycline, and metronidazole. Antimicrob Agents Chemother. 1994 May;38(5):1157-60. PubMed PMID: 8067755; PubMed Central PMCID: PMC188168. 6: Mackey-Lawrence NM, Petri WA Jr. Amoebic dysentery. BMJ Clin Evid. 2011 Jan 13;2011. pii: 0918. Review. PubMed PMID: 21477391; PubMed Central PMCID: PMC3275292. 7: American Academy of Pediatrics Committee on Drugs: Clioquinol (iodochlorhydroxyquin, vioform) and iodoquinol (diiodohydroxyquin): blindness and neuropathy. Pediatrics. 1990 Nov;86(5):797-8. PubMed PMID: 2146587. 8: Marie C, Petri WA Jr. Amoebic dysentery. BMJ Clin Evid. 2013 Aug 30;2013. pii: 0918. Review. PubMed PMID: 23991750; PubMed Central PMCID: PMC3758071. 9: Chang HR, Lee JJ, Lin CB. Pleural empyema secondary to rupture of amoebic liver abscess. Intern Med. 2012;51(5):471-4. Epub 2012 Mar 1. PubMed PMID: 22382561. 10: Banik GR, Barratt JL, Marriott D, Harkness J, Ellis JT, Stark D. A case-controlled study of Dientamoeba fragilis infections in children. Parasitology. 2011 Jun;138(7):819-23. doi: 10.1017/S0031182011000448. Epub 2011 Apr 27. PubMed PMID: 21524324. 11: Roberts T, Ellis J, Harkness J, Marriott D, Stark D. Treatment failure in patients with chronic Blastocystis infection. J Med Microbiol. 2014 Feb;63(Pt 2):252-7. doi: 10.1099/jmm.0.065508-0. Epub 2013 Nov 15. PubMed PMID: 24243286. 12: Levine GI. Sexually transmitted parasitic diseases. Prim Care. 1991 Mar;18(1):101-28. Review. PubMed PMID: 2011632. 13: Ali NW, Gamal M, Abdelkawy M. Chromatographic methods for simultaneous determination of diiodohydroxyquinoline and metronidazole in their binary mixture. Pak J Pharm Sci. 2013 Sep;26(5):865-71. PubMed PMID: 24035940. 14: Arnò B, Coletta A, Tesauro C, Zuccaro L, Fiorani P, Lentini S, Galloni P, Conte V, Floris B, Desideri A. A small organic compound enhances the religation reaction of human topoisomerase I and identifies crucial elements for the religation mechanism. Biosci Rep. 2013 Mar 7;33(2):e00025. doi: 10.1042/BSR20120118. PubMed PMID: 23368812; PubMed Central PMCID: PMC3590572. 15: Stark D, Barratt J, Roberts T, Marriott D, Harkness J, Ellis J. A review of the clinical presentation of dientamoebiasis. Am J Trop Med Hyg. 2010 Apr;82(4):614-9. doi: 10.4269/ajtmh.2010.09-0478. PubMed PMID: 20348509; PubMed Central PMCID: PMC2844584. 16: Kim SY, Lee MJ, Kim JW, Na YR, Lee HY, Cho H, Lee KB, Lee YM, Lee C, Park H, Yang EG. Effects of clioquinol analogues on the hypoxia-inducible factor pathway and intracelullar mobilization of metal ions. Biol Pharm Bull. 2012;35(12):2160-9. PubMed PMID: 23207768. 17: Ibrahim TM, Iheonunekwu N, Gill V, Vantapool H. Differentiating amoebic ulcero-haemorrhagic recto-colitis from idiopathic inflammatory bowel disease: still a diagnostic dilemma. West Indian Med J. 2005 Jun;54(3):210-2. PubMed PMID: 16209229. 18: Samuelson JC, Burke A, Courval JM. Susceptibility of an emetine-resistant mutant of Entamoeba histolytica to multiple drugs and to channel blockers. Antimicrob Agents Chemother. 1992 Nov;36(11):2392-7. PubMed PMID: 1283295; PubMed Central PMCID: PMC284341. 19: Markell EK, Udkow MP. Blastocystis hominis: pathogen or fellow traveler? Am J Trop Med Hyg. 1986 Sep;35(5):1023-6. PubMed PMID: 3766850. 20: Mansour-Ghanaei F, Dehbashi N, Yazdanparast K, Shafaghi A. Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis. World J Gastroenterol. 2003 Aug;9(8):1832-3. PubMed PMID: 12918131; PubMed Central PMCID: PMC4611554.